BiotechTube
Zumutor Biologics

Zumutor Biologics

Cambridge, United States· Est.
zumutor.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Zumutor Biologics is a private, pre-revenue biotechnology company advancing a pipeline of novel NK cell-targeting immunotherapies. Its lead asset, ZM008, is a first-in-class anti-LLT1 antibody currently in Phase 1 clinical trials for solid tumors, representing a key clinical validation point for its platform. The company leverages a dual geographic strategy with operations in the US and India, and is backed by venture capital investors including Accel Partners and IDG Ventures.

OncologyImmunology

Technology Platform

INABLR™ - A proprietary human antibody discovery platform comprising high-diversity naïve and synthetic libraries, integrated with a unique ADCC (Antibody-Dependent Cellular Cytotoxicity) improvement platform for enhancing the potency of therapeutic antibodies.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

The growing focus on innate immunity and NK cell therapies presents a major opportunity to address limitations of current T-cell-centric immunotherapies, particularly in cold tumors.
Zumutor's first-in-class anti-LLT1 antibody, ZM008, could establish a novel checkpoint inhibitor class.
The company's cost-efficient R&D model in India provides a strategic advantage in capital-efficient drug development.

Risk Factors

High risk associated with the novel, unvalidated LLT1 target; clinical failure would be a major setback.
As a small, private company, it faces significant financing risk to fund expensive clinical trials.
Intense competition in the immuno-oncology space from larger, well-resourced companies poses a commercial threat.

Competitive Landscape

Zumutor competes in the rapidly evolving NK cell immunotherapy space, facing competition from companies developing antibody-based NK cell engagers (e.g., Innate Pharma, Affimed) and cellular NK therapies. Its first-in-class focus on LLT1 provides niche differentiation, but it must compete for funding, clinical mindshare, and ultimately, partnership or acquisition interest against numerous other novel IO targets.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →